中粮生物科技股份有限公司 关于召开 2025 年第 4 次临时股东大会的提示性公告 证券代码：000930 证券简称：中粮科技 公告编号：2025-067 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 中粮生物科技股份有限公司（以下简称公司）已于 2025 年 8 月 22 日在《中 国证券报》《证券时报》《证券日报》《上海证券报》和巨潮资讯网 （www.cninfo.com.cn）上刊登了《中粮科技：关于召开 2025 年第 4 次临时股东 大会的通知》（公告编号：2025-064）。为保护投资者的合法权益，方便公司股 东行使股东大会表决权，本次股东大会将通过深圳证券交易所系统及互联网投票 系统向社会公众股股东提供网络形式的投票平台。现发布公司关于召开 2025 年 第 4 次临时股东大会的提示性公告如下： 一、召开会议的基本情况 门规章、规范性文件和《公司章程》等相关规定和要求。 现场会议召开时间：2025 年 9 月 8 日（星期一）14:30 网络投票时间：通过深交所交易系统进行网络投票时间为 2025 年 9 月 8 日 日 9:15-15:00。 公 ...

Group 1 - A new company, Guangxi Hechi Pinsheng Biotechnology Co., Ltd., has been established with a registered capital of 10 million yuan [1] - The business scope of the company includes animal diagnosis and treatment, artificial breeding of nationally protected terrestrial wild animals, and production of experimental animals [1] - The company is wholly owned by Huace Testing [1]

Core Insights - Institutional investors, including public funds, brokerages, and social security funds, are increasingly focusing on stocks related to the "new quality productivity" concept, indicating a significant trend towards innovation and technology-driven sectors [1][4]. Group 1: Institutional Holdings - As of the end of Q2 2023, public funds, brokerages, and social security funds collectively held shares in 145 stocks, with 89 of these stocks belonging to the new quality productivity concept [1]. - Social security funds appeared among the top ten shareholders in 568 listed companies, with a total holding value of approximately 165.07 billion yuan, including significant stakes in companies like Sany Heavy Industry and Transsion Holdings [2]. - Public funds held shares in 5,205 A-share companies, with a total market value of 6.03 trillion yuan, while brokerages held shares in 820 companies valued at 85.02 billion yuan [2]. Group 2: Investment Strategies - Social security funds prioritize safety, yield, and liquidity, focusing on long-term value, while public funds balance risk and return across various products, and brokerages emphasize market opportunity capture [3]. - All three types of institutions share a common interest in investing in sectors aligned with national policies and industrial upgrades, particularly in high-tech fields such as advanced manufacturing and artificial intelligence [4]. Group 3: Sector Focus - The 89 stocks held by these institutions are primarily distributed across industries such as hardware, machinery, and biomedicine, reflecting a concentrated interest in sectors that support technological advancement [5].

证券代码：600165 证券简称：ST 宁科 公告编号：2025-096 宁夏中科生物科技股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次股东会的召集人是公司董事会，表决方式符合《中华人民共和国公司法》 及《公司章程》的规定，会议由董事长符杰先生主持。 议案名称：关于公司新增关联关系及 2025 年度日常关联交易预计的议案 审议结果：通过 表决情况： | | | 同意 | | | 反对 | | 弃权 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 股东类型 比例 | | | | 比例 | | | 比例 | | | | 票数 | | 票数 | | | 票数 | | | | | | （%） | | （%） | | | （%） | | | A股 | 218,998,690 | 99.4761 | 1,105,500 | 0.5021 | 47,800 | 0.0218 | | | (二) | 涉及重大事项，5%以下股东的 ...

Core Points - The board of directors of Fujian Wancheng Biotechnology Group Co., Ltd. held its 33rd meeting on September 2, 2025, to discuss various resolutions [1] - The board approved the nomination of Ms. Yang Fan as an independent director candidate, pending approval from the shareholders' meeting [2] - The board also approved the appointment of Mr. You Zilin as the company secretary and the designation of Mr. Wang Zenin and Mr. You Zilin as authorized representatives for the company in compliance with Hong Kong Listing Rules [2] - A report on the usage of previously raised funds was approved, covering the period up to June 30, 2025, and was reviewed by an external accounting firm [2] - The board agreed to establish internal governance systems to enhance company operations and compliance with relevant laws and regulations [2][4] - The company plans to hold its third extraordinary shareholders' meeting on September 18, 2025, to discuss the aforementioned resolutions [4]

Group 1 - The Hang Seng Hong Kong Stock Connect Innovative Drug Index decreased by 0.2%, while the CSI Hong Kong Stock Connect Medical and Health Comprehensive Index fell by 0.1%. Conversely, the CSI Innovative Drug Industry Index, CSI Biotechnology Theme Index, and CSI 300 Medical and Health Index all increased by 0.1% [1] - The Hang Seng Innovative Drug ETF (159316) experienced a growth of approximately 1 billion yuan in size over the past month, reaching a new historical high of nearly 2 billion yuan [1] Group 2 - The Hang Seng Innovative Drug ETF tracks the Hang Seng Hong Kong Stock Connect Innovative Drug Index, which focuses on leading innovative drug companies in Hong Kong, comprising no more than 40 stocks involved in innovative drug research, development, and production [2] - The CSI Hong Kong Stock Connect Medical and Health Comprehensive Index has been tracking since 2017 and includes 50 stocks from the medical device, biopharmaceutical, chemical drug, and other sectors within the Hong Kong Stock Connect [2] - The CSI Innovative Drug Industry Index focuses on leading innovative drug companies in the A-share market, consisting of no more than 50 stocks involved in innovative drug research and development [2] - The CSI Biotechnology Theme Index targets leading biotechnology companies in the A-share market, including no more than 50 stocks involved in gene diagnosis, biopharmaceuticals, and other human biotechnology sectors [2] - The CSI 300 Medical and Health Index covers leading companies in the medical and health industry within the CSI 300 Index, encompassing various segments of the future health industry, including chemical pharmaceuticals, medical services, and medical devices [2]

Group 1 - The core point of the article is that NuoVas (SH 688105) announced a share reduction plan by its shareholder Guoshou Chengda, which holds approximately 30.96 million shares, accounting for 7.78% of the company's total share capital [1] - Guoshou Chengda plans to reduce its holdings by up to approximately 11.93 million shares, which is not more than 3% of the total share capital, through block trading and centralized bidding within three months after the announcement [1] - The revenue composition for NuoVas in 2024 is as follows: 85.17% from research and experimental development, 14.66% from pharmaceutical manufacturing, and 0.17% from other businesses [1] Group 2 - As of the announcement, NuoVas has a market capitalization of 9.5 billion yuan [1]

Group 1 - Deutsche Bank has regained a position in the Eurozone's Stoxx 50 index after being excluded for seven years, alongside Siemens Energy and Argenx SE [1] - The inclusion comes after Deutsche Bank's market value has more than doubled in the past 12 months, reflecting a rebound in European bank stocks [1] - Siemens Energy's stock has increased over twofold since September last year, benefiting from a surge in global electricity demand [1] Group 2 - The index company also announced adjustments to the broader Stoxx Europe 600 index, including the addition of French biotech company Abivax SA and Fraport AG, while removing Gerresheimer AG [2] - All changes to the index will take effect after the European market opens on September 22 [2]

Core Viewpoint - The recent patent application by Central South University and Shengxiang Biotechnology Co., Ltd. focuses on a novel reagent composition and kit for liver cancer detection, which significantly enhances the sensitivity and specificity of early screening compared to traditional methods [1] Group 1: Patent Details - The invention pertains to the field of biological detection technology, specifically a reagent composition and kit for liver cancer detection [1] - The reagent composition includes primers and probes for detecting the methylation status of specific genes associated with liver cancer, namely FAM109B, RIMS2, SNX31, FAR1, and FLJ26850 [1] Group 2: Detection Advantages - The proposed reagent composition allows for non-invasive liver cancer screening, which is a significant improvement over conventional liver ultrasound and alpha-fetoprotein combined testing [1] - The new method greatly increases detection sensitivity and accuracy for early liver cancer screening, while substantially reducing misdiagnosis and missed diagnosis rates [1]

Group 1 - The company has reviewed the list of incentive recipients for the 2025 restricted stock incentive plan and confirmed that all recipients meet the necessary legal and regulatory conditions [1][2] - The incentive recipients do not include independent directors, foreign employees, or shareholders holding 5% or more of the company's shares [2] - The first grant date for the incentive plan is set for September 2, 2025, with a total of 10 recipients receiving restricted stock [2]